This is the authors' abstract. We don't add key points for this paper.
. In addition to discussing wide ranging conceptual implications, I also describe ongoing efforts at the pharmaceutical company Sanofi to employ the resulting 'semi-synthetic organisms' or SSOs, for the production of next-generation protein therapeutics. This article is part of the theme issue 'Reactivity and mechanism in chemical and synthetic biology'.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Floyd E. Romesberg (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: